Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-07-17 , DOI: 10.1111/1759-7714.14076
Jianhua Shi ₁ , Guimin Chen ₁ , Haitao Wang ₂ , Xiuxiu Wang ₁ , Baohui Han ₃ , Kai Li ₄ , Qiming Wang _{5,

6} , Li Zhang ₇ , Zhehai Wang ₈ , Ying Cheng ₉ , Jianxing He ₁₀ , Yuankai Shi ₁₁ , Weiqiang Chen ₁₂ , Yi Luo ₁₃ , Lin Wu ₁₃ , Xiuwen Wang ₁₄ , Kejun Nan ₁₅ , Faguang Jin ₁₆ , Jian Dong ₁₇ , Baolan Li ₁₈ , Zhian Liu ₁

Affiliation

Department of Oncology, Linyi Cancer Hospital, Linyi, China.
Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Department of Thoracic Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China.
Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Department of Internal Medicine, Henan Cancer Hospital, Zhengzhou, China.
Department of Respiratory Diseases, Peking Union Medical College Hospital, Beijing, China.
Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan, China.
Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
Department of Pulmonary Medicine, Lanzhou Military General Hospital, Lanzhou, China.
Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China.
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Respiratory Diseases, Tang Du Hospital, Xi'an, China.
First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China.
Department of General Medicine, Capital Medical University, Beijing Chest Hospital, Beijing, China.

There is a lack of targeted therapeutic options for squamous cell lung cancer (SCC). Accelerated hypertension is an issue with many targeted therapies for lung cancer. This study aimed to analyze the efficacy of anlotinib, based on progression-free survival (PFS) and overall survival (OS) in patients with SCC, stratified by hypertension and Eastern Cooperative Oncology Group (ECOG) score.

中文翻译：

三线安罗替尼期间发生高血压与鳞状细胞肺癌 (SCC) 患者的无进展生存期相关：ALTER0303 试验的事后分析

鳞状细胞肺癌 (SCC) 缺乏靶向治疗选择。加速高血压是许多肺癌靶向治疗的一个问题。本研究旨在根据高血压和东部肿瘤协作组 (ECOG) 评分分层的 SCC 患者的无进展生存期 (PFS) 和总生存期 (OS) 分析安罗替尼的疗效。

更新日期：2021-09-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11